Krajina: Švédsko
Jazyk: švédčina
Zdroj: Läkemedelsverket (Medical Products Agency)
alfuzosinhydroklorid
Hexal AG
G04CA01
alfuzosin hydrochloride
10 mg
Depottablett
laktosmonohydrat Hjälpämne; alfuzosinhydroklorid 10 mg Aktiv substans
Apotek
Receptbelagt
Alfuzosin
Förpacknings: Blister, 50 tabletter; Blister, 30 tabletter; Blister, 60 tabletter; Blister, 60 x 1 tabletter (endos); Blister, 100 tabletter; Blister, 180 tabletter; Blister, 20 tabletter; Blister, 10 tabletter; Blister, 90 tabletter
Avregistrerad
2004-06-04
PACKAGE LEAFLET: INFORMATION FOR THE USER ALFURO 10 MG PROLONGED-RELEASE TABLETS Alfuzosin hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Alfuro is and what it is used for 2. What you need to know before you take Alfuro 3. How to take Alfuro 4. Possible side effects 5. How to store Alfuro 6. Contents of the pack and other information 1. WHAT ALFURO IS AND WHAT IT IS USED FOR Alfuro belongs to a group of medicines called alpha-adrenoreceptor antagonists or alpha-blockers. It is used to treat moderate to severe symptoms caused by an enlarged prostate gland, a condition that is also called benign prostatic hyperplasia. Enlarged prostate glands can cause urinary problems such as frequent and difficult urination, especially at night. Alpha-blockers relax the muscles in the prostate and bladder neck. This allows urine to flow out of the bladder more easily. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ALFURO _DO NOT TAKE ALFURO _ if you are allergic to alfuzosin, other quinazolines (e.g. terazosin, doxazosin, prazosin) or any of the other ingredients of this medicine (listed in section 6). if you suffer from conditions that cause a marked drop in blood pressure when standing up. if you have liver problems. if you take other medicines that belong to the group of alpha-blockers. _WARNINGS AND PRECAUTIONS_ Talk to your doctor or pharmacist before taking Alfuro. if you have severe kidney problems, since the safety of Alfuro has not been established in these patients. Prečítajte si celý dokument
Produktinformationen för Alfuro 10 mg depottablett, MTnr 19284, gäller vid det tillfälle då läkemedlet godkändes. Informationen kommer inte att uppdateras eftersom läkemedlet inte marknadsförs i Sverige. Av samma anledning finns inte någon svensk produktinformation. Den engelska produktinformationen kommer dock att uppdateras för de produkter där Sverige är referensland. Om läkemedelsnamnet i följande produktinformation inte stämmer med namnet på dokumentet, beror det på att läkemedlet i Sverige är godkänt under ett annat namn. SUMMARY OF THE PRODUCT CHARACTERISTICS 1. N AME OF THE M EDICINAL P RODUCT Alfuro 10 mg prolonged-release tablets 2. Q UALITATIVE AND Q UANTITATIVE C OMPOSITION Each tablet contains 10 mg alfuzosin hydrochloride. Excipients with known effect: Each tablet contains 8 mg Lactose monohydrate. For the full list of excipients, see section 6.1. 3. P HARMACEUTICAL F ORM Prolonged-release tablet. White, round, bevelled-edge, uncoated tablets. 4. C LINICAL P ARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of moderate to severe functional symptoms of benign prostatic hyperplasia (BPH). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The prolonged-release tablet should be swallowed whole with a sufficient amount of fluid. _Adults_ 1 prolonged-release tablet 10 mg once daily. The first dose should be taken at bedtime. The tablet should be taken immediately after the same meal each day. _Elderly (over 65 years)_ As adults. Pharmacokinetic and clinical safety data demonstrate that dose reduction is usually not necessary to elderly patients. _Reduced renal function_ Mild to moderate renal insufficiency (creatinine clearance 30ml/min): Dose reduction is usually not necessary (see section 5.2). Severe renal insufficiency (creatinine clearance < 30ml/min): Alfuro 10 mg should not be given to patients with severely impaired renal function as there are no clinical safety data available for this patient group (see section 4.4). _Hepatic insufficiency_ Alfuro given as 10 mg prolonged release t Prečítajte si celý dokument